XML 24 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net loss $ (7,590,099) $ (23,103,864)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 4,862,267 5,515,518
Stock compensation 1,138,585 1,379,080
Gain on sale of real estate assets, net (5,444,792) (3,426,572)
Employee Bonuses paid with CDT stock 0 172,421
Asset Impairment Charges 6,443,437 1,969,311
Amortization of financing costs 281,245 351,291
Amortization of below-market leases (4,753) (4,641)
Straight-line rent adjustment 261,483 (152,722)
Changes in operating assets and liabilities:    
Other assets 355,913 82,575
Deferred tax asset 75,257 48,117
Accounts payable and accrued liabilities 186,636 (1,001,301)
Deferred leasing costs (148,148) (502,946)
Accrued real estate taxes (187,448) 19,390
Net cash provided by (used in) operating activities 417,870 (728,060)
Cash flows from investing activities:    
Real estate acquisitions (9,444,465) (9,729,351)
Additions to buildings and tenant improvements (2,703,012) (2,273,726)
Investment in marketable securities 0 (2,362)
Proceeds from sale of marketable securities 13,990 105,206
Proceeds from sales of real estate, net 25,625,377 24,767,052
Net cash provided by investing activities 13,491,890 12,866,819
Cash flows from financing activities:    
Proceeds from mortgage notes payable, net of issuance costs 18,942,396 22,272,291
Payment of debt issuance costs (424,002) (335,724)
Repayment of mortgage notes payable (28,862,783) (27,897,127)
Payment of deferred offering costs (343,514) 0
Distributions to noncontrolling interests (1,277,913) (3,629,964)
Contributions from noncontrolling interests 0 200,000
Dividends paid to Series D Preferred Stockholders (2,295,607) (2,236,696)
Net cash used in financing activities (14,523,897) (10,612,691)
Net (decrease) increase in cash equivalents and restricted cash (614,137) 1,526,068
Cash, cash equivalents and restricted cash - beginning of period 8,036,496 6,510,428
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation 7,422,359 8,036,496
Supplemental disclosure of cash flow information:    
Income taxes paid 78,848 46,511
Non-cash investing activities:    
Paid building and tenant improvements from prior year (207,847) (295,567)
Private warrants from Conduit Pharmaceuticals 0 642,600
Non-cash financing activities:    
Unpaid deferred offering costs 6,589 0
Unpaid building and tenant improvements 361,261 207,847
Dividends payable - Preferred Stock Series D 190,220 194,784
CDT Common Stock [Member]    
Non-cash financing activities:    
Payment of accrued bonus to ex-CFO with CDT stock 0 124,357
Distribution of CDT stock to employees 0 172,421
Mortgage Notes [Member]    
Supplemental disclosure of cash flow information:    
Interest paid-mortgage notes payable 5,906,234 5,371,017
Common Class A [Member]    
Cash flows from financing activities:    
Issuance of Series A Common Stock, net of offering costs 1,667,120 0
Repurchase of Series A Common Stock, at cost (1,585,091) (140,416)
Series D Preferred Stock [Member]    
Cash flows from financing activities:    
Issuance of Series A Common Stock, net of offering costs 0 1,195,855
Repurchase of Series D Preferred Stock, at cost (344,503) (40,910)
Non-cash financing activities:    
Dividends payable - Preferred Stock Series D 190,220 194,784
Conduit Pharmaceuticals Inc [Member]    
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Net loss (gain) in fair value marketable securities 188,287 17,925,723
All Other Than Conduit [Member]    
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Net loss (gain) in fair value marketable securities $ 0 $ 560